A netrin domain-containing protein secreted by the human hookworm Necator americanus protects against CD4 T cell transfer colitis
A netrin domain-containing protein secreted by the human hookworm Necator americanus protects against CD4 T cell transfer colitis
复制标题
DOI:
10.1016/j.trsl.2021.02.012
复制
发表时间:
2021-05-04
影响因子:
7.8
通讯作者:
Loukas,Alex
中科院分区:
文献类型:
--
作者:
Buitrago,Geraldine;Pickering,Darren;Loukas,Alex
The symbiotic relationships shared between humans and their gastrointestinal parasites present opportunities to discover novel therapies for inflammatory diseases. A prime example of this phenomenon is the interaction of humans and roundworms such as the hookworm,Necator americanus. Epidemiological observations, animal studies and clinical trials using experimental human hookworm infection show that hookworms can suppress inflammation in a safe and well-tolerated way, and that the key to their immunomodulatory properties lies within their secreted proteome. Herein we describe the identification of 2 netrin domain-containing proteins from theN. americanussecretome, and explore their potential in treating intestinal inflammation in mouse models of ulcerative colitis. One of these proteins, subsequently namedNa-AIP-1, was effective at suppressing disease when administered prophylactically in the acute TNBS-induced model of colitis. This protective effect was validated in the more robust CD4 T cell transfer model of chronic colitis, where prophylacticNa-AIP-1 reduced T-cell-dependent type-1 cytokine responses in the intestine and the associated intestinal pathology. Mechanistic studies revealed that depletion of CD11c+ cells abrogated the protective anticolitic effect ofNa-AIP-1. Next generation sequencing of colon tissue in the T-cell transfer model of colitis revealed thatNa-AIP-1 induced a transcriptomic profile associated with the downregulation of metabolic and signaling pathways involved in type-1 inflammation, notably TNF. Finally, co-culture ofNa-AIP-1 with a human monocyte-derived M1 macrophage cell line resulted in significantly reduced secretion of TNF.Na-AIP-1 is now a candidate for clinical development as a novel therapeutic for the treatment of human inflammatory bowel diseases.